Avicanna Announces Late Filing of Financial Statements and Application for Management Cease Trade Order
TORONTO, March 31, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. ('Avicanna' or 'Company') (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, announces that it will miss the deadline of March 31, 2025 ('Filing Deadline') to file the Company's audited consolidated financial statements for the year ended December 31, 2024 as required by National Instrument 51-102 and the Company's Management's Discussion & Analysis for the year ended December 31, 2024 (the 'Documents'). The Company's auditor, Ramirez Jimenez International CPAs ('RJI') informed the Company that although the audit work is substantially complete and they are prepared to issue the audit opinion, they are not able to do so prior to the filing deadline of March 31, 2025, due to unexpected matters.
RJI has substantially finalized the 2024-year end audit engagement and has obtained a third-party engagement quality review (an EQR); however, due to the internal-RJI personnel and jurisdictional licensing issue that recently arose, RJI will not be able to issue the audit report by the filing deadline. RJI is addressing the matter and anticipates that it will not take more than two weeks to resolve the matter and issue the audit opinion, at which time the Company will also file the MD&A and Annual Information Form.
Accordingly, the Company has informed staff of the Ontario Securities Commission about its anticipated delay in filing the Documents and has applied to the Ontario Securities Commission pursuant to Part 4 of National Policy 12-203 – Management Cease Trade Orders ('NP 12-203') for a Management Cease Trade Order ('MCTO') pending the filing of the Documents, which MCTO will prohibit the Company's management from trading in the securities of the Company until such time as the Documents are filed.
No decision has yet been made by the Ontario Securities Commission on this application. The Ontario Securities Commission may grant the application and issue the Management Cease Trade Order, or it may impose an issuer cease trade order. There can be no assurance that a MCTO will be issued.
The Company will comply with the alternative information guidelines set out in Section 9 of NP 12-203 and will file bi-weekly default status reports in the form of press releases. The Company anticipates and expects to file the Documents by April 15, 2025.
The Company also announces the 2024 Full Year Earnings Conference Call scheduled for April 1, 2025, which was previously announced on March 18, 2025, will be postponed to a later date.
About Avicanna:
Avicanna is a commercial-stage international biopharmaceutical company focused on the advancement and commercialization of cannabinoid-based products and formulations for the global medical and pharmaceutical market segments. Avicanna has an established scientific platform including R&D and clinical development leading to the commercialization of more than thirty proprietary, evidence-based finished products and supporting four commercial stage business pillars.
Medical Cannabis formulary (RHO Phyto™): The formulary offers a diverse range of proprietary products including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids, supported by ongoing patient and medical community education. RHO Phyto is an established brand in Canada currently available nationwide across several channels and expanding into new international markets.
Medical cannabis care platform (MyMedi.ca): MyMedi.ca is a medical cannabis care platform formed with the aim to better serve medical cannabis patients' needs and enhance the medical cannabis patients' journey. MyMedi.ca is operated by Northern Green Canada Inc. and features a diverse portfolio of products and bilingual pharmacist-led patient support programs. MyMedi.ca also provides specialty services to distinct patient groups such as veterans and collaborates with public and private payers for adjudication and reimbursement. MyMedi.ca provides educational resources to the medical community to facilitate the incorporation of medical cannabis into health care regimens.
Pharmaceutical pipeline: Leveraging Avicanna's scientific platform, vertical integration, and real-world evidence, Avicanna has developed a pipeline of proprietary, indication-specific cannabinoid-based candidates that are in various stages of clinical development. These cannabinoid-based candidates aim to address unmet needs in the areas of dermatology, chronic pain, and various neurological disorders.
Active pharmaceutical ingredients (Aureus Santa Marta™): Active pharmaceutical ingredients supplied by the Company's majority owned subsidiary Santa Marta Golden Hemp SAS ('SMGH') is a commercial-stage business dedicated to providing various forms of high-quality CBD, THC and CBG to the Company's international partners for use in the development and production of food, cosmetics, medical, and pharmaceutical products. SMGH also forms part of the Company's supply chain and is a source of reliable input products for its consumer retail, medical cannabis, and pharmaceutical products globally.
SOURCE Avicanna Inc.
Stay Connected
For more information about Avicanna, visit our website or contact Ivana Maric by email at info@avicanna.com.
Cautionary Note Regarding Forward-Looking Information and Statements
This news release contains 'forward-looking information' within the meaning of applicable securities laws. Forward-looking information contained in this news release may be identified by the use of words such as, 'may', 'would', 'could', 'will', 'likely', 'expect', 'anticipate', 'believe', 'intend', 'plan', 'forecast', 'project', 'estimate', 'outlook' and other similar expressions. Forward-looking information contained in this news release includes, without limitation, statements related to the Offering, the use of proceeds of the Offering, the receipt of all approvals of the Toronto Stock Exchange in connection with the Offering, statements with respect to the Company's future business operations, the opinions or beliefs of management and future business goals. Although the Company believes that the expectations and assumptions on which such forward looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to current and future market conditions, including the market price of the common shares of the Company, and the risk factors set out in the Company's annual information form dated April 1, 2024, filed with the Canadian securities regulators and available under the Company's profile on SEDAR+ at www.sedarplus.ca. The statements in this news release are made as of the date of this release. The Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
3 hours ago
- Business Insider
Associated Capital announces voluntary NYSE delisting, SEC deregistration
Associated Capital (AC) Group announced that it has given formal notice to the New York Stock Exchange of its intention to voluntarily delist its Class A common stock from the NYSE and to deregister under Section 12(b) of the Securities Exchange Act of 1934. Following the de-listing from the NYSE, we expect to provide liquidity to AC's Class A stock shareholders by listing AC Class A on the OTCQX platform. AC plans on filing a Form 25 with the U.S. SEC on or about August 25. The last day of trading in AC's common stock on the NYSE will be on or about September 4, when the Form 25 takes effect. Ninety days thereafter, AC's common stock deregistration is expected to become effective. When AC files Form 15 on or about September 4, its filing obligations under the Exchange Act will immediately be suspended or terminated, including the filing of all reports on Forms 8-K, 10-Q and 10-K. AC has filed an application for its common stock to be quoted on the OTCQX platform, operated by OTC Markets Group Inc. AC will continue to provide information to its stockholders and to take such actions to enable a trading market in its common stock to exist. There is no guarantee, however, that a broker will continue to make a market in the common stock and that trading of the common stock will continue on the OTCQX or otherwise or that the company will continue to provide information sufficient to enable brokers to provide quotes for its common stock. Elevate Your Investing Strategy:
Yahoo
4 hours ago
- Yahoo
Is It Too Late to Buy Celestica Stock?
Written by Aditya Raghunath at The Motley Fool Canada Valued at a market cap of $33 billion, Celestica (TSX:CLS) is a TSX stock that has been on an absolute tear in the last 12 months, rising close to 300%. Moreover, in the past decade, Celestica stock has returned an emphatic 1,560%, crushing broader market returns by a wide margin. As past returns are not reflective of future gains, let's see if you should own this TSX tech stock at the current valuation. How did Celestica stock perform in Q2 2025? Celestica is a global electronics manufacturing services provider offering comprehensive supply chain solutions through two segments: Advanced Technology Solutions and Connectivity and Cloud Solutions. It provides design, development, manufacturing, assembly, testing, systems integration, and after-market services to original equipment manufacturers and cloud service providers. Celestica serves diverse markets, including the aerospace and defence, industrial, HealthTech, capital equipment, communications, and enterprise sectors, with particular strength in hyperscale data centre infrastructure manufacturing. Celestica stock represents a compelling investment opportunity as the company rides the unprecedented wave of AI-driven data centre expansion. The electronics manufacturing services provider delivered exceptional Q2 results, with revenue of $2.9 billion and adjusted earnings per share of $1.39, both exceeding guidance ranges. The investment thesis centers on Celestica's dominant position in networking infrastructure for hyperscale customers. Its Communications and Cloud Solutions (CCS) segment grew by 28% year-over-year, driven by explosive demand for 800G networking switches alongside continued strength in 400G products. Notably, 800G volumes reached parity with 400G in Q2, with every major 400G customer transitioning to 800G platforms. This positions Celestica to capture market share gains as hyperscalers like Google, Amazon, and Microsoft rapidly expand their AI infrastructure. Management remains optimistic about near-term growth as it forecasts revenue of $11.6 billion in 2025, an increase of 20% year over year. Comparatively, adjusted earnings are forecast to increase by 20% to $5.50 per share. Celestica reported an operating margin of 7.4% in Q2, a quarterly record and expects free cash flow to total $400 million this year. Celestica's competitive moat stems from its globally diversified manufacturing footprint across 16 countries, providing customers with supply chain resilience and geographic flexibility. The company has proven manufacturing readiness with capacity to support $3–4 billion in additional revenue across key locations, including Thailand, Mexico, and Texas. This scalability advantage is crucial as hyperscalers continue aggressive capital expenditure spending on AI infrastructure. Is the TSX stock still undervalued? Analysts tracking Celestica stock forecast revenue to rise from $9.6 billion in 2024 to $19.2 billion in 2028. Its adjusted earnings are forecast to expand from $3.88 per share to $11.2 per share in this period. Today, the TSX tech stock trades at 34 times forward earnings, which is much higher compared to its historical multiple of 10.4 times. If CLS stock is priced at 30 times forward earnings, it should trade around $336 in early 2028, indicating upside potential of 18% from current levels. The secular tailwinds supporting Celestica's growth remain robust. Hyperscaler customers are in early innings of multi-year AI infrastructure buildouts, with recent capital expenditure increases from major cloud providers validating the sustained demand environment. The upcoming transition to 1.6T networking and next-generation AI/ML compute platforms provides additional growth catalysts extending through 2026–2027. Trading at reasonable valuations despite exceptional fundamentals, Celestica stock offers investors direct exposure to the AI infrastructure boom through a proven execution partner with market-leading capabilities, strong customer relationships, and operating leverage at volume scale. The post Is It Too Late to Buy Celestica Stock? appeared first on The Motley Fool Canada. Should you invest $1,000 in Shopify right now? Before you buy stock in Shopify, consider this: The Motley Fool Stock Advisor Canada analyst team identified what they believe are the 15 best stocks for investors to buy now… and Shopify wasn't one of them. The 15 stocks that made the cut could potentially produce monster returns in the coming years. Consider MercadoLibre, which we first recommended on January 8, 2014 … if you invested $1,000 in the 'eBay of Latin America' at the time of our recommendation, you'd have $24,427.64!* Now, it's worth noting Stock Advisor Canada's total average return is 94%* – a market-crushing outperformance compared to 61%* for the S&P/TSX Composite Index. Don't miss out on our top 15 list, available when you join Stock Advisor Canada. See the 15 Stocks * Returns as of July 15th, 2025 More reading 10 Stocks Every Canadian Should Own in 2025 3 Canadian Companies Powering the AI Revolution Fool contributor Aditya Raghunath has no position in any of the stocks mentioned. The Motley Fool recommends Alphabet, Amazon, and Microsoft. The Motley Fool has a disclosure policy. 2025 Sign in to access your portfolio
Business Upturn
4 hours ago
- Business Upturn
LEADING EDGE MATERIALS ANNOUNCES CLOSING OF PREVIOUSLY ANNOUNCED NON-BROKERED PRIVATE PLACEMENT
By GlobeNewswire Published on August 16, 2025, 02:30 IST LEADING EDGE MATERIALS ANNOUNCES CLOSING OF PREVIOUSLY ANNOUNCED NON-BROKERED PRIVATE PLACEMENT NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAWS. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER, OR A SOLICITATION OF ANY OFFER, TO BUY OR SUBSCRIBE FOR ANY SECURITIES IN LEADING EDGE MATERIALS IN ANY JURISDICTION. Vancouver, August 15, 2025 – Leading Edge Materials Corp. ('Leading Edge Materials' or the 'Company') (TSXV: LEM) (Nasdaq First North: LEMSE) (OTCQB: LEMIF) announces announce the closing of the non-brokered private placement financing (the 'Private Placement') previously announced on June 10, 2025. Pursuant to the Private Placement, the Company has issued 17,738,500 units (the 'Units') at a price of C$0.16 per Unit for aggregate gross proceeds of C$2,838,160. Each Unit consists of one (1) common share (each, a 'Common Share') in the capital of the Company and one (1) Common Share purchase warrant (a 'Warrant'). Each Warrant will entitle the holder to purchase one Common Share (a 'Warrant Share') at a price of C$0.32 per Warrant Share until the date which is four (4) years from the closing date of the Private Placement (the 'Closing Date'). Leading Edge Materials intends to use net proceeds for the Company's projects, located in Sweden and Romania and for general working capital and corporate purposes. A finder's fee of 6% was paid to arm's length third party on a portion of the Private Placement. The Private Placement is subject to final approval from the TSX Venture Exchange (the 'Exchange'). The securities issued pursuant to the Private Placement are subject to applicable statutory resale restrictions, including a hold period expiring on December 15, 2025, pursuant to applicable Canadian securities laws. Insiders of the Company purchased a total of 10,666,000 Units under the Private Placement which constitutes a 'related party transaction' as defined under Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions ('MI 61-101'). The Company relied on exemptions from the formal valuation and minority shareholder approval requirements of MI 61-101 based on the fact that neither the fair market value of the Units subscribed for by the insiders, nor the consideration for the Units paid by such insiders, exceeded 25% of the Company's market capitalization as determined in accordance with MI 61-101. Mr. Eric Krafft, a director of the Company, has subscribed for and acquired 10,666,000 Common Shares under the Private Placement. Prior to the Private Placement, Mr. Krafft beneficially owned and controlled 85,056,577 Common Shares and 22,852,173 warrants of the Company. Mr. Krafft is a Control Person (as defined by the policies of the Exchange), beneficially holding 95,722,577 common shares and 33,518,173 warrants of the Company, representing approximately 38.30% of the issued and outstanding Common Shares on a non-diluted basis, and 48.28% on a partially diluted basis, assuming the exercise of warrants held by Mr. Krafft only. The Company obtained disinterested shareholder approval at the Annual General Meeting held on July 24, 2020 for Mr. Krafft to become a Control Person of the Company. Eric Krafft has acquired the Units for investment purposes and has a long-term view of his investment. In the future, Mr. Krafft may take such actions in respect of his investment in the Company as he may deem appropriate, depending on the market conditions and circumstances at that time. The foregoing disclosure regarding Mr. Krafft's holdings is being disseminated pursuant to National Instrument 62-103 The Early Warning System and Related Take-Over Bid and Insider Reporting Issues (NI 62-103). A copy of Mr. Krafft's early warning report will appear on the Company's profile on SEDAR Plus. The information herein with respect to the number of Mr. Krafft's securities and his intention relating thereto are not within the knowledge of the Company and are provided by Mr. Krafft. The securities have not been, and will not be, registered under the U.S. Securities Act, or any United States state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from the registration requirements of the U.S. Securities Act and applicable United States state securities laws. This press release shall not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. This news release is not a prospectus under Regulation (EU) 2017/1129 (the 'EU Prospectus Regulation'). The Company has not authorized any offer of securities to the public (as defined in the EU Prospectus Regulation) in any EEA member state and no such prospectus has been or will be prepared in connection with the Private Placement. On behalf of the Board of Directors, Leading Edge Materials Corp. Kurt Budge, CEO For further information, please contact the Company at: [email protected] Follow usTwitter: Linkedin: About Leading Edge Materials Leading Edge Materials is a Canadian public company focused on developing a portfolio of critical raw material projects located in the European Union. Critical raw materials are determined as such by the European Union based on their economic importance and supply risk. They are directly linked to high growth technologies such as lithium-ion batteries and permanent magnets for electric motors, wind turbines and defense applications. The portfolio of projects includes the 100% owned Woxna Graphite mine (Sweden), 100% owned Norra Kärr Heavy Rare Earth Elements project (Sweden) and the 51% owned Bihor Sud Nickel Cobalt exploration alliance (Romania). Additional Information This information is information that Leading Edge Materials Corp. is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, at August 15, 2025 at 2:30 PM Vancouver time. Leading Edge Materials is listed on the TSXV under the symbol 'LEM', OTCQB under the symbol 'LEMIF' and Nasdaq First North Stockholm under the symbol 'LEMSE'. Svensk Kapitalmarknadsgranskning ('SKMG') is the Company's Certified Adviser for the Nasdaq First North Growth Market (Stockholm) and may be contacted via email [email protected] or by phone +46 (0)8 913 008. Reader Advisory This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Leading Edge Materials in any jurisdiction. This news release may include forward-looking information that is subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward-looking, including statements with respect to the closing of the Private Placement, the receipt of regulatory approvals, and the use of proceeds from the Private Placement. Although the Company believes the expectations expressed in such forward-looking information are based on reasonable assumptions, such information is not a guarantee of future performance and actual results or developments may differ materially from those contained in forward-looking information. Factors that could cause actual results to differ materially from those in forward-looking information include, but are not limited to, fluctuations in market prices, successes of the operations of the Company, the Company's ability to close the Private Placement, the Company's ability to obtain the required regulatory approvals, continued availability of capital and financing and general economic, market or business conditions. There can be no assurances that such information will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. The Company does not assume any obligation to update any forward-looking information except as required under the applicable securities laws. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Important information for EEA Investors The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions. The recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such restrictions. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Leading Edge Materials in any jurisdiction. Any investment decision in connection with the Private Placement must be made on the basis of all publicly available information relating to the Company and the Company's shares/Units. The information contained in this announcement is for background purposes only and does not purport to be full or complete. No reliance may be placed for any purpose on the information contained in this announcement or its accuracy or completeness. This announcement does not purport to identify or suggest the risks (direct or indirect) which may be associated with an investment in the Company or the new shares/Units. This press release is not a prospectus for the purposes of the EU Prospectus Regulation. Leading Edge Materials has not authorized any offer to the public of Units, shares or rights in any member state of the EEA and no prospectus has been or will be prepared in connection with the Private Placement. In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, 'qualified investors' who are (i) persons having professional experience in matters relating to investments who fall within the definition of 'investment professionals' in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the 'Order'); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as 'relevant persons'). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this document and should not act or rely on it. Attachment LEM – 2025 News Release Annoucing Closing of Financing-final Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
